A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

Clinical trial NCT02533453 · COMPLETED

Trial details

NCT number: NCT02533453
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Type 2 Diabetes Mellitus

Start date: 2016-01-28
Primary completion: 2016-12-07
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.